Latest Innovation News

SPC Global reported a 27% rise in normalised EBITDA for FY26 to $38.5 million, supported by a $100 million equity raise that halved net leverage. The company’s strategic pivot to higher-margin branded products and operational efficiencies set the stage for targeted double-digit revenue and EBITDA growth in FY27.

OpenLearning Limited accelerated its SaaS revenue growth to a record $3.27 million in HY2026, boosting gross margin to 63% and cutting its EBITDA loss by over a quarter amid expanding multi-year institutional contracts.

Helloworld Travel (ASX:HLO) is rapidly expanding its Australian retail footprint with 14 new stores opened or committed in the past 18 months, alongside the full acquisition of Mobile Travel Agents (MTA), Australia's largest home-based travel network. This growth underscores strong confidence in the Helloworld brand and the enduring demand for expert travel advice.

Constellation Technologies (ASX:CT1) reported a 5% revenue decline to $1.71 million and a $458,246 net loss for FY26, weighed down by delayed hardware deployments and increased expenses. Recurring subscription revenue grew 22%, reflecting ongoing customer engagement.

Cobram Estate Olives (ASX:CBO) posted an 11.3% revenue increase to A$268.9 million in FY2026 but swung to a A$4.2 million net loss as costs surged and integration expenses weighed. The company declared a steady fully franked dividend of 4.5 cents per share.

WAM Active Limited delivered a historic 75.5% investment portfolio return in FY2026, driving net profit after tax up 355% to $33.8 million and declaring fully franked dividends totaling 9.4 cents per share.

PEXA Group delivered a solid FY26 with 7% revenue growth and a return to profitability, while facing a regulatory pricing review that could reshape its future investment capacity.

SomnoMed reported a 3% revenue rise to $114.5 million and a 19% EBITDA increase to $10.9 million in FY26, navigating European market headwinds and a CEO transition while launching its Virtus device targeting sleep apnea with bruxism.

Saluda Medical delivered FY26 revenue of US$90.2 million, beating guidance with strong US and international growth, while reporting a flat net loss of US$149.6 million amid ongoing heavy investment. The company’s FDA approval of its CAP24 paddle lead opens a new US surgical market segment.

Mach7 Technologies reported a 17.4% revenue drop to $27.9 million and a 44% increase in net loss to $8.9 million for FY26, driven by a strategic transition to a subscription model and cost base restructuring.

Imricor Medical Systems and Philips have launched a combined interventional MR lab solution integrating Philips’ 1.5T BlueSeal MRI with Imricor’s MR-compatible systems, targeting cardiac electrophysiology and setting a new standard for MR-guided interventions.

McMillan Shakespeare (ASX:MMS) reported a 13.8% rise in underlying net profit after tax and amortisation to $107.9 million for FY26, driven by strong novated lease growth and accelerating electric vehicle adoption.